Should You Buy Jazz Pharmaceuticals PLC (JAZZ) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
Buy JAZZ now. The stock has pulled back into a key support zone (~164) while fundamentals and Street outlook improved meaningfully on strong Phase 3 zanidatamab (Ziihera) data. Near-term technical momentum is weak, but options positioning is notably bullish (calls dominating, low put demand) and sell-side targets imply large upside from current levels. With no proprietary Intellectia buy signals today, this is a fundamentals + sentiment-driven buy into support rather than a momentum chase.
Technical Analysis
Price/levels: Last ~164.06, sitting right on S1 (164.116) with next support S2 ~161.816; upside levels are Pivot ~167.839 then R1 ~171.561.
Trend/momentum: MACD histogram is negative (-0.573) and expanding lower, signaling bearish momentum in the very near term. RSI(6) ~35.3 is near oversold territory (weak but closer to a potential bounce zone than a fresh breakdown signal). Moving averages are converging, suggesting consolidation after the prior move rather than a clean trend.
Tactical read: Technically this is a "buy-at-support" setup (164 area) with a likely first rebound target back toward ~168 (pivot). A clean break below ~162 would invalidate the support-based thesis.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Strongly improving. Since mid-Nov 2025, the dominant action has been repeated price target raises and reaffirmed Buy/Overweight/Outperform ratings following positive HERIZON-GEA-01 results (and follow-on data discussions).
Notable changes: Piper raised PT to $219 (from $147); BofA raised to $263 (from $247) and explicitly defended approval/peak-sales outlook; Morgan Stanley raised to $225; Wells to $235; Truist to $220; Jefferies to $225; RBC to $194; Baird to $209. UBS is the main dissenting voice, downgrading to Neutral with PT $188 after the rally, citing more balanced risk/reward and fewer major near-term catalysts.
Wall Street pros: (1) Late-stage oncology asset with strong Phase 3 readout and multi-indication upside potential; (2) improving long-term revenue diversification narrative; (3) multiple firms see peak-sales potential around $1B+ to $2B+ depending on indication breadth.
Wall Street cons: (1) Some believe upside is more limited after the big rerating; (2) nearer-term catalyst cadence may be lighter until the next major updates/earnings; (3) execution/approval timing still matters even if probability looks high.
Influential/political trading check: No recent congress trading data available; hedge fund and insider trends are both reported as Neutral with no significant recent activity.
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188 USD and a high forecast of 263 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188 USD and a high forecast of 263 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 165.410
Current: 165.410
